Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma

Fig. 5

Suppression of SIRT6 potentiates doxorubicin-induced suppression of in vivo growth of osteosarcoma cells. a KHOS/NP cells were transfected with empty vectors, shRNA for SIRT6, or wild-type SIRT6, and 2.5 × 106 KHOS/NP cells were injected into the marrow space of the right proximal tibia under anesthesia. Two weeks after tumor cell inoculation, doxorubicin (4 mg/kg in DMSO, once a week) was injected intraperitoneally. Macroscopic and microscopic images were acquired after euthanizing mice 20 days after the start of doxorubicin treatment. Immunohistochemical staining for SIRT6 was performed in resected tumors. b The tumor volume was measured every five days. The tumor volumes were calculated as “length x width x height x 0.52”. c Weight of tumors measured after resection. d Immunohistochemical staining for Ki67 was performed in resected tumors and the percentage of Ki67-positive cells was evaluated for each experimental group. e The number of TUNEL-positive cells was counted in ten microscopic images obtained at high-power magnification (x400 magnification) for each tumor. *; P < 0.05, **; P < 0.001

Back to article page